atopic dermatitis

Pfizer’s Abrocitinib yields positive results in phase 3 moderate to severe AD trial
Pfizer’s Abrocitinib yields positive results in phase 3 moderate to severe AD trial
Pharmaceutical Business Review
Pfizer
clinical trials
PF-04965842
atopic dermatitis
Flag link:
Why Dermira Stock Jumped Again Today
Why Dermira Stock Jumped Again Today
Motley Fool
Demira
lebrikizumab
atopic dermatitis
Flag link:
Microbiome Report for Week Ending 3/9/19
Microbiome Report for Week Ending 3/9/19
CP Wire
microbiome
Synlogic
AOBiome
AbbVie
Infant Bacterial Therapeutics
IBD
atopic dermatitis
Flag link:
FDA approves Dupixent for atopic dermatitis in adolescents
FDA approves Dupixent for atopic dermatitis in adolescents
BioCentury
Dupixent
Regeneron
Sanofi
FDA
atopic dermatitis
Flag link:
Lilly and Incyte's Olumiant Hits the Mark in Two Phase III Atopic Dermatitis Trials
Lilly and Incyte's Olumiant Hits the Mark in Two Phase III Atopic Dermatitis Trials
BioSpace
Eli Lilly
Incyte
olumiant
atopic dermatitis
clinical trials
Flag link:
Microbiome Report for Week Ending 12/1/18
Microbiome Report for Week Ending 12/1/18
CP Wire
microbiome
Evelo Biosciences
Kaleido Biosciences
Vedanta Biosciences
psoriasis
atopic dermatitis
IBD
Flag link:
Microbiome Report for Week Ending 12/1/18
Evelo Biosciences
Kaleido Biosciences
Vedanta Biosciences
psoriasis
atopic dermatitis
IBD
Flag link:
Going gangbusters in atopic dermatitis, the FDA hands Sanofi and Regeneron a fresh coup for their mega-blockbuster star Dupixent
Going gangbusters in atopic dermatitis, the FDA hands Sanofi and Regeneron a fresh coup for their mega-blockbuster star Dupixent
Endpoints
Sanofi
Regeneron
Dupixent
atopic dermatitis
Flag link:
Sanofi unveils eczema drug data, as regulators mull label expansion
Sanofi unveils eczema drug data, as regulators mull label expansion
Pharmaforum
Sanofi
Dupixent
dupilumab
eczema
atopic dermatitis
Flag link:
After back-to-back trial flops, Realm slashes its staff, halts research work and ponders a fire sale
After back-to-back trial flops, Realm slashes its staff, halts research work and ponders a fire sale
Endpoints
Realm Therapeutics
atopic dermatitis
clinical trials
layoffs
Flag link:
Realm Craters As Another Phase II Trial Fails to Reach Endpoints
Realm Craters As Another Phase II Trial Fails to Reach Endpoints
BioSpace
Realm Therapeutics
atopic dermatitis
clinical trials
PR022
Flag link:
Novartis to Pay as Much as $1 Billion for Rights to Skin Drug
Novartis to Pay as Much as $1 Billion for Rights to Skin Drug
Yahoo/Bloomberg
Novartis
Galapagos
MorphoSys
MOR106
atopic dermatitis
Flag link:
Dermavant inks $330M deal for GSK's phase 3-ready psoriasis drug
Dermavant inks $330M deal for GSK's phase 3-ready psoriasis drug
Fierce Biotech
GSK
Dermavant
Roivant
CSO
tapinarof
psoriasis
atopic dermatitis
Flag link:
Sanofi's Dupixent scores NICE recommendation after price cut
Sanofi's Dupixent scores NICE recommendation after price cut
Fierce Pharma
Sanofi
NICE
atopic dermatitis
Dupixent
Flag link:
Great data! Huge potential! (Too bad it failed the primary endpoint)
Great data! Huge potential! (Too bad it failed the primary endpoint)
Endpoints
Vanda Pharmaceuticals
tradipitant
atopic dermatitis
Flag link:
AbbVie preps JAK atopic dermatitis candidate for phase 3
AbbVie preps JAK atopic dermatitis candidate for phase 3
Fierce Biotech
AbbVie
JAK inhibitors
clinical trials
atopic dermatitis
Upadacitinib
Sanofi
Regeneron
Dupixent
Flag link:
AbbVie adds more stellar data on ABT-494 — this time for atopic dermatitis
AbbVie adds more stellar data on ABT-494 — this time for atopic dermatitis
Endpoints
AbbVie
ABT-494
atopic dermatitis
Upadacitinib
Flag link:
Is Another Blockbuster Drug on the Way for Regeneron Pharmaceuticals, Inc.?
Is Another Blockbuster Drug on the Way for Regeneron Pharmaceuticals, Inc.?
Motley Fool
Regeneron
Dupixent
Sanofi
atopic dermatitis
Flag link:
Galderma licenses PhII atopic dermatitis drug from Roche’s Chugai
Galderma licenses PhII atopic dermatitis drug from Roche’s Chugai
Fierce Biotech
Galderms
atopic dermatitis
Roche
Chugai
nemolizumab
Flag link:
Regeneron Pharmaceuticals Inc Jumps on Positive Clinical Data
Regeneron Pharmaceuticals Inc Jumps on Positive Clinical Data
Motley Fool
Regeneron
clinical trials
dupilumab
eczema
atopic dermatitis
Flag link:

Pages